Thurston Springer Miller Herd & Titak’s Regeneron Pharmaceuticals REGN Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$4.72K	–	1183
2025 Q2	$4.72K	Hold	9	–	–	﹤0.01%	1298
2025 Q1	$5.71K	Buy	9 +1	+13%	+$688	﹤0.01%	1247
2024 Q4	$5.7K	Buy	8 +2	+33%	+$1.68K	﹤0.01%	990
2024 Q3	$6.31K	Hold	6	–	–	﹤0.01%	1146
2024 Q2	$6.31K	Buy	+6	New	+$5.82K	﹤0.01%	1137

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's REGN Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 9 shares — an estimated $4.72K sold.

Thurston Springer Miller Herd & Titak first reported a position in REGN in Q2 2024 and held it in 5 quarters. The position peaked at $6.31K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Thurston Springer Miller Herd & Titak reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Thurston Springer Miller Herd & Titak sold 9 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $4.72K.
Thurston Springer Miller Herd & Titak first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 5 quarters.
Thurston Springer Miller Herd & Titak's Regeneron Pharmaceuticals position peaked at $6.31K in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.